3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
51
Other hematologic neoplasm
39
Plasma cell
2
Gastrointestinal
2
Thoracic
1
Myeloid
1
Genitourinary
1
Classical hematology
1
Breast
1
Conditions
Recurrence
1
Neoplasm Metastasis
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Carboplatin
1145
Cisplatin
874
Pemetrexed
832
pembrolizumab
604
Paclitaxel
597
Docetaxel
535
Gemcitabine
424
Radiotherapy
374
Erlotinib Hydrochloride
367
Nivolumab
322
Bevacizumab
322
Etoposide
294
durvalumab
254
Drug Therapy
233
osimertinib
217
atezolizumab
207
Radiosurgery
188
Gefitinib
177
Vinorelbine
145
130-nm albumin-bound paclitaxel
123
Magnetic Resonance Spectroscopy
120
Ipilimumab
118
Cetuximab
113
anlotinib
104
tislelizumab
103
Topotecan
101
Cyclophosphamide
101
Taxes
99
Irinotecan
95
Albumin-Bound Paclitaxel
92
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
idelalisib
×
Thoracic
×
Clear all
NCT03257722
2024-02-28
PIL
Augusta University
Phase 1/2
Terminated
4 enrolled
5 charts